A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 48
- Registration Number
- NCT06401044
- Locations
- 🇺🇸
Ppd Las Vegas Research Unit, Las Vegas, Nevada, United States
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 20
- Registration Number
- NCT06352892
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 535
- Registration Number
- NCT06131398
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷Gustave Roussy, Villejuif, France
🇺🇸City of Hope National Medical Center, Duarte, California, United States
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT06088199
- Locations
- 🇺🇸
Endeavor Health Clinical Trials Center, Skokie, Illinois, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Affiliated Dermatology, Scottsdale, Arizona, United States
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 100
- Registration Number
- NCT06079476
- Locations
- 🇮🇳
Sir Ganga Ram Hospital, New Delhi, Delhi, India
🇮🇳Apollo Hospital, New Delhi, Delhi, India
🇮🇳Stavya Spine Hospital and Research Institute SSHRI, Ahmedabad, Gujarat, India
A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Amgen
- Registration Number
- NCT06061523
A Study of CCX168 in Japanese and Caucasian Healthy Adult Males
- Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 80
- Registration Number
- NCT05988008
- Locations
- 🇯🇵
Sumida Hospital, SOUSEIKAI Global Clinical Research Center, Sumida City, Tokyo, Japan
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 25
- Registration Number
- NCT05481411
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Inland Empire Clinical Trials, LLC, Rialto, California, United States
🇺🇸The Texas Liver Institute, Inc., San Antonio, Texas, United States
A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 145
- Registration Number
- NCT05048784
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT04987333
- Locations
- 🇬🇧
Labcorp Clinical Research Unit - Leeds, Leeds, LDS, United Kingdom